3 results
The primary safety endpoint is to evaluate a 30-day major adverse event (MAE) rate, where MAE is a composite of the following device- or procedure-related events: * All-cause mortality* Stroke* Life-threatening bleeding (MVARC scale)* Major vascular…
Primary Objective: What is the reliability and repeatabily of CAD/CAM systems in measuring stump volume in transtibial amputee patients? Is there a significant difference in measured stumpvolumes in patients per system?Secondary Objective(s): Are…
The purpose of this study is to characterize the safety and tolerability of OAV101 IT in participants who have discontinued treatment with nusinersen (Spinraza®) or risdiplam (Evrysdi®). The data from this study will expand on the data generated…